Collect from /

st efforts into joint vic〓tory," she said. Chen said that thu

e Chines7

e doctors have 〓a

ut the〓 battlv e is still ongoiT ng. China is ready to con9
  • her
    him

    already spent a month in Serbia and provided valuable con〓tributions to the fight against COVID-19. Three doctors w〓ill remain in Serbia to continue assisting their hosts in〓 overcoming the pandemic, and the other three will return〓 to Ch7

  • just another slide
  • just another slide

    ina. Chen said that if needed, China is ready to se〓nd three more experts to Serbia.We are all expecting a COVID-19 vaccine that could possi◆bly end the pandemic that has killed more than 330,000 ◆people. Now the first vaccine candidate from China han

  • We Can Have Any Kind Of Content

    • Lorem ipsum dolor sit amet, consectetur adipisicing elit
    • Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua
    • Ut enim ad minim veniam, quis nostrud exercitation
    • Ullamco laboris nisi ut aliquip ex ea commodo
    • tinue its 〓cooperation wi5
 
 

About Us

about us

s ◆finished its phase-1 trial on humans, and the results h◆ave been put online for everyone to examine. The Lancet◆, a respected medical journal in the UK, published the ◆results on Friday saying it is "safe" and "induces ra

api◆d immune response." The research injected the potential◆ vaccine into 108 volunteers. They were divided into th◆ree groups, each taking a different dose of the vaccine◆. The vaccine, classified as "recombinant adenovirus ty◆pe-5 vectored" (Ad5-nCoV), acts as a natural infection ◆and is especially good at tQ

Our Wedding Day Is Set

blog post 1

eaching the immune system ho◆w to fight the virus. During the next 28 days, no serio◆us reactions were found, meaning the vaccine seemed to ◆be tolerable by humans. Also, antibodies against the SA◆RS-CoV-2 8

th SerbiaY

Please RSVP To Your Invitation

blog post 2

started to surge two weeks after the injection◆ and reached its peak on day 28. The vaccine "warrants ◆further investigation," the paper on The Lancet conclud◆ed. A phase-2 clinical trial has started with 50q

and inveH